[Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer].

Chen, Qing; Li, Yan; Zhang, Wenjie; Yang, Shengjie; Wang, Chen; Guo, Qisen; Shi, Wenna

Chen, Qing; Li, Yan; Zhang, Wenjie; Yang, Shengjie; Wang, Chen; Guo, Qisen; Shi, Wenna.

Afiliação

Chen Q; Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Li Y; Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Zhang W; Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Yang S; Weifang Medical University, Weifang 261000, China.
Wang C; Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Guo Q; Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Shi W; Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.

Zhongguo Fei Ai Za Zhi ; 24(9): 605-612, 2021 Sep 20.

Article em Zh | MEDLINE | ID: mdl-34455735

Assuntos

Antineoplásicos; Carcinoma Pulmonar de Células não Pequenas; Docetaxel; Inibidores de Checkpoint Imunológico; Neoplasias Pulmonares; Idoso; Antineoplásicos/efeitos adversos; Antineoplásicos/uso terapêutico; Antígeno B7-H1/antagonistas & inibidores; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Carcinoma Pulmonar de Células não Pequenas/mortalidade; Carcinoma Pulmonar de Células não Pequenas/patologia; Docetaxel/efeitos adversos; Docetaxel/uso terapêutico; Feminino; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos; Inibidores de Checkpoint Imunológico/uso terapêutico; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/mortalidade; Neoplasias Pulmonares/patologia; Masculino; Pessoa de Meia-Idade; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Estudos Retrospectivos

Palavras-chave

Docetaxel; Efficacy; Lung neoplasms; PD-1/PD-L1 inhibitor; Safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Docetaxel / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhongguo Fei Ai Za Zhi Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google